[go: up one dir, main page]

ZA200405853B - Use of adapalene for the treatment of dermatological disorders - Google Patents

Use of adapalene for the treatment of dermatological disorders

Info

Publication number
ZA200405853B
ZA200405853B ZA200405853A ZA200405853A ZA200405853B ZA 200405853 B ZA200405853 B ZA 200405853B ZA 200405853 A ZA200405853 A ZA 200405853A ZA 200405853 A ZA200405853 A ZA 200405853A ZA 200405853 B ZA200405853 B ZA 200405853B
Authority
ZA
South Africa
Prior art keywords
adapalene
treatment
dermatological disorders
dermatological
disorders
Prior art date
Application number
ZA200405853A
Inventor
Graeber Michael
Czernielewski Janusz
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of ZA200405853B publication Critical patent/ZA200405853B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
ZA200405853A 2002-03-12 2004-07-22 Use of adapalene for the treatment of dermatological disorders ZA200405853B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0203070A FR2837101B1 (en) 2002-03-12 2002-03-12 USE OF 6- [1-ADAMANTYL) -4-METHOXYPHENYL] -2- NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS

Publications (1)

Publication Number Publication Date
ZA200405853B true ZA200405853B (en) 2008-10-29

Family

ID=27772059

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200405853A ZA200405853B (en) 2002-03-12 2004-07-22 Use of adapalene for the treatment of dermatological disorders

Country Status (4)

Country Link
KR (1) KR101007161B1 (en)
AR (1) AR038924A1 (en)
FR (1) FR2837101B1 (en)
ZA (1) ZA200405853B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100798853B1 (en) * 2005-02-15 2008-01-28 (주)한국스티펠 Pharmaceutical composition for the prevention and treatment of vitiligo with retinoids as an active ingredient
FR2901701B1 (en) * 2006-05-31 2010-10-29 Galderma Res & Dev COMPOSITIONS COMPRISING AT LEAST ONE NAPHTHOIC ACID DERIVATIVE AND AT LEAST ONE FILMOGENIC AGENT, PROCESSES FOR THEIR PREPARATION, AND USES THEREOF
FR2903603B1 (en) 2006-07-13 2009-03-20 Galderma Res & Dev S N C Snc COMBINATION OF ADAPALENE AND BENZOLEO PEROXIDE IN THE TREATMENT OF ACNE
EP2097075A1 (en) * 2006-11-20 2009-09-09 Galderma Research & Development, S.N.C. Use of adapalene for modulating the expression of cd1d or il-10
EP2097076A1 (en) * 2006-11-20 2009-09-09 Galderma Research & Development, S.N.C. Use of adapalene for modulating the expression of il-1ra
JP2013518920A (en) 2010-02-09 2013-05-23 ガルデルマ・リサーチ・アンド・デヴェロップメント Dermatological composition comprising a combination of adapalene and benzoyl peroxide for the treatment of acne with reduced post-inflammatory pigmentation in non-Caucasian races
EP2563357B1 (en) 2010-04-29 2018-10-17 Galderma Research & Development Adapalene 0.3% for use in a method for treating scars
US20150126608A1 (en) 2012-05-25 2015-05-07 Galderma Research & Development Treatment of preadolescent moderate acne vulgaris
US10653659B2 (en) 2014-11-20 2020-05-19 Galderma S.A. Compositions comprising a compound from the family of avermectins and an agonist compound for at least one of the retinoic acid receptors for treating acne
KR102486502B1 (en) * 2015-09-15 2023-01-09 주식회사 엘지생활건강 Soluble microneedle patch for delivery of anti-acne drug

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85849A1 (en) * 1985-04-11 1986-11-05 Cird BENZONAPHTHALENIC DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THE PHARMACEUTICAL AND COSMETIC FIELDS
FR2730930B1 (en) * 1995-02-27 1997-04-04 Oreal USE OF NO-SYNTHASE INHIBITORS TO REDUCE THE IRRITANT SKIN EFFECT OF PRODUCTS USED IN THE COSMETIC OR PHARMACEUTICAL FIELD

Also Published As

Publication number Publication date
KR101007161B1 (en) 2011-01-12
FR2837101B1 (en) 2004-07-02
AR038924A1 (en) 2005-02-02
KR20040111394A (en) 2004-12-31
FR2837101A1 (en) 2003-09-19

Similar Documents

Publication Publication Date Title
AU2003286567A8 (en) Methods for the treatment of skin disorders
IL160389A0 (en) Use of flibanserin for the treatment of sexual disorders
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
IL209842A0 (en) Compounds for the treatment of metabolic disorders
IL163725A0 (en) Administration of agents for the treatment of inflammation
PL378108A1 (en) Combination therapy for the treatment of immunoinflammatory disorders
AU2003228819A8 (en) Combinations for the treatment of inflammatory skin disorders
AU2003300791A1 (en) Combination therapy for the treatment of pain
AU2003286728A8 (en) Compounds for the treatment of metabolic disorders
GB0223367D0 (en) Therapeutic treatment
GB0213869D0 (en) The treatment of pain
ZA200405853B (en) Use of adapalene for the treatment of dermatological disorders
GB0219660D0 (en) Therapeutic use
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
GB0223854D0 (en) Therapeutic treatment
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
GB0210464D0 (en) Therapeutic treatment
ZA200505996B (en) Combination therapy for the treatment of immunoinflammatory disorders
AU2003209542A8 (en) Use of s-substituted l-crysteine for the manufacture of a medicament for the treatment of dermatological disorders
IL164951A0 (en) The treatment of pain with lfendropil
GB0201025D0 (en) The treatment of degenerative diseases
AU2003274885A1 (en) Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders
HRP20041159A2 (en) Combination for the treatment of airway disorders